| Identification | Back Directory | [Name]
CI 934 | [CAS]
91188-00-0 | [Synonyms]
CI 934
PD-114843
Aids007688
91188-00-0
Aids-007688
Quinolone cl-934
Merafloxacin (CI-934)
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
3-Quinolinecarboxylic acid, 1-ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo- | [Molecular Formula]
C19H23F2N3O3 | [MOL File]
91188-00-0.mol | [Molecular Weight]
379.4 |
| Chemical Properties | Back Directory | [Melting point ]
200-220.45 °C | [Boiling point ]
545.8±50.0 °C(Predicted) | [density ]
1.304±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 11.11 mg/mL (29.28 mM; ultrasonic and adjust pH to 3 with HCl) | [form ]
Solid | [pka]
6.44±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria[1][2].
Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively[1]. | [References]
[1]. Sun Y, et, al. Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro. bioRxiv. 2020 Oct 21;2020.10.21.349225. [2]. Mandell W, et, al. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852-7. |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://www.approvedhomemanagement.com/ShowSupplierProductsList927327/0.htm |
|